Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL
A phase 3 trial of Glucarpidase in Acute lymphoblastic leukaemia, run by Nordic Society for Pediatric Hematology and Oncology, completed.
Overview
Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL is a phase 3 interventional study registered as NCT01305655 by Nordic Society for Pediatric Hematology and Oncology, with 47 participants recorded, started 2008-07 and reaching its primary completion in 2014-12. Interventions recorded: Glucarpidase. Conditions recorded: Acute Lymphoblastic Leukemia (ALL).
Linked to the drug Glucarpidase because the registry names it among its interventions and Acute lymphoblastic leukaemia among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialHigh Dose Methotrexate With Leucovorin Rescue With or Without Glucarpidase in Osteosarcoma
Shares Glucarpidase and the tag pipeline.
- TrialWill Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?
Shares Glucarpidase and the tag pipeline.
- TrialStudy of YK012 in B-cell Acute Lymphoblastic Leukemia
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialAZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialA Study of CTD402 in T-ALL/LBL Patients
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialCAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialMoxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialStudy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Shares Acute lymphoblastic leukaemia and the tag pipeline.